- Sola International Inc.
- Intuitive Surgical Inc.
- Zimmer Biomet Holdings Inc.
- Implex Corp.
- Orthofix Medical Inc.
- Breg Inc.
- OraSure Technologies Inc.
- Affymetrix Inc.
- General Electric Co.
- GE Healthcare Bio-Sciences Inc.
- Amersham Health
- GE Healthcare Technologies Inc.
- Abbott Laboratories Inc.
- Abbott Point of Care
- Pharmion Corp.
- Myogen Inc.
- Teva Pharmaceutical Industries Ltd.
- Sicor Inc.
- Aventis SA
- CSL Ltd.
- Cephalon Inc.
- CIMA Labs Inc.
- Eli Lilly & Co.
- Applied Molecular Evolution Inc.
- Merck & Co. Inc.
- GlaxoSmithKline PLC
- NeuroSearch AS
- AstraZeneca PLC
- Boehringer Ingelheim Fremont Inc.
- Sola International completes $99mm FOPO
- Intuitive Surgical nets $79mm with FOPO
- Zimmer acquires Implex for cash and stock
- Orthofix acquiring ortho rehab company Breg
- OraSure Technologies completes FOPO
- Affymetrix offers $100mm in convertible debt
- GE acquires Amersham PLC for £5.7bn
- Abbott to market i-Stat products; deal ends
- Abbott buys i-Stat in deal worth $392mm
- Pharmion nets $76.2mm with IPO
- Myogen nets $74.9mm with 5.75mm share IPO
- Teva acquires Sicor for $3.3bn in cash and stock
- CSL to acquire Aventis Behring for up to €760.5mm
- Cephalon buys CIMA for $492mm in cash
- Lilly acquires AME for stock and cash
- Merck & Co., Actelion in CHF350mm cardio-renal alliance; terminated
- Merck, Neurogen sign alliance to develop pain therapeutics; terminated
- GSK, NeuroSearch renew CNS deal; concluded
- Abgenix, AstraZeneca develop monoclonal antibodies for cancer
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. email@example.com.
All fields are required.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.